Thymodepressin: crystalline salt development — US8138221B2
Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu · 2012 · US8138221B2 · patent family 39535926
Published 2012-03-20.
Reported patent results
Reported findings
The potassium example reports high analytical purity and low measured water content.
Physicochemical development of Thymodepressin salt forms; the granted US claims narrow to a particular potassium crystal.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Potassium-salt quality | 98.3% HPLC peak-area purity; water content 0.7% | Crystalline material characterized by diffraction; not a clinical efficacy endpoint |
| Preparation recovery | Reported quantitative yield in the potassium example | Manufacturing recovery, not response or bioavailability |
Other salts in the description are not automatically within the granted claim. Analytical quality does not establish comparative clinical effectiveness or safety.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The disclosure discusses several salts, but the granted US claims narrow to a specified potassium crystal form.
The broader abstract is not the granted claim set; a crystal-form patent does not establish superiority in clinical treatment.
- Publication
- US8138221B2 ↗ · 2012-03-20
- Earliest priority / filing
- 2006-12-19 / 2007-12-13
- Original applicant / assignee
- Apotex Technologies Inc
- Indexed status
- Expired - Fee Related · checked 2026-11-06
- Patent family
- 39535926 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture
Inventors: Tim Fat Tam; Blaise N'Zemba; Regis Leung-Toung; Yingsheng Wang; Yanqing Zhao; Lily Yu.
US8138221B2 · US8735602B2 · EP2121729A4 · KR20090108034A · CN101611050B · AU2007335212B2 · CA2571645A1 · CL2007003680A1 · MX2009006673A · PE20121642A1 · RU2536685C2 · TWI406872B · UA106580C2 · UY30798A1 · WO2008074128A1
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The broader abstract is not the granted claim set; a crystal-form patent does not establish superiority in clinical treatment.
- Other salts in the description are not automatically within the granted claim. Analytical quality does not establish comparative clinical effectiveness or safety.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-39535926. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu. Thymodepressin: crystalline salt development — US8138221B2 US8138221B2 · patent family 39535926 2012.
Molekul research summary: https://molekul.io/research/patent-us8138221b2. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry